NCT02988817: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors |
|
|
| Completed | 1/2 | 306 | Europe, US | Enapotamab vedotin (HuMax-AXL-ADC) | Genmab | Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC), Thyroid Cancer, Melanoma, Sarcoma, Solid Tumors | 11/21 | 11/21 | | |
